Oncolytics Biotech Appoints Andrew Aromando as Chief Business Officer to Enhance Business Growth

Oncolytics Biotech Appoints Andrew Aromando as Chief Business Officer

Oncolytics Biotech® Inc., a prominent clinical-stage company focusing on immunotherapy for cancer treatment, has made headlines with its recent appointment of Andrew Aromando as the new Chief Business Officer. This strategic move comes as the company seeks to fortify its business development strategy, particularly around its innovative cancer therapy, pelareorep.

A Proven Leader in the Life Sciences

Andrew Aromando carries a robust background in the life sciences field, having dedicated over three decades to various roles in oncology-focused biopharma. His most recent position was at Ambrx Biopharma as the Chief Operating Officer, where he played a critical role in the company’s acquisition by Johnson & Johnson, valued at an impressive $2 billion. Aromando's expertise extends beyond mere operational leadership; he has a solid track record in strategic planning, corporate development, and product commercialization.

In his new role at Oncolytics, Aromando will spearhead global business initiatives, focusing on corporate, clinical, and regulatory strategies. His immediate priority will be leveraging the extensive clinical data associated with pelareorep, which is in trial phases for treating various cancers, including pancreatic, breast, and anal cancers.

Vision for Enhanced Patient Outcomes

Jared Kelly, the CEO of Oncolytics, expressed high expectations regarding Aromando's extensive industry experience. According to Kelly, Aromando’s leadership is expected to significantly expedite clinical and business strategies aimed at maximizing the potential of pelareorep within an accelerated timeline. Aromando himself stated that he is excited to join Oncolytics at such a pivotal time, particularly given the promising data surrounding the company’s therapeutic offerings in difficult-to-treat cancers.

Pelareorep is an intravenously administered immunotherapeutic agent that has shown remarkable efficacy in changing the tumor microenvironment, effectively transforming